Just did a deep dive into ASX cannabis stocks and honestly there's way more happening in Australia's medical marijuana sector than I thought. The market's been absolutely booming - spending jumped from AU$234 million in 2022 to AU$400 million in the first half of 2024 alone. That's wild growth.

So I looked at the 10 biggest players by market cap and it's interesting how diverse they are. Botanix Pharmaceuticals is leading the charge at AU$786 million market cap with their skin treatment product that actually got FDA approval last year. Then you've got smaller but solid players like Little Green Pharma doing AU$27 million revenue in just three quarters - they're exporting to Europe and actually turning a profit.

What caught me off guard is how many of these companies are already operating internationally. Althea's in Canada with their recreational cannabis division, Ecofibre's focused on hemp in the US, and Cann Group's been doing research since 2017. The whole ecosystem feels more mature than I expected.

The forecasts are pretty optimistic too - analysts reckon the market could grow at 33.6% annually through 2030. Makes sense when you see the pipeline of new treatments, especially for neurological stuff like autism spectrum disorder.

If you're looking at Australian shares in this space, the diversity is actually good - you've got pure-play medical marijuana companies, manufacturing specialists, and biotech plays. Not all of them are huge, but they're all doing something different. Anyone else been tracking these medical marijuana australia shares or am I just noticing this now?